This dissertation describes the development of HIV protease inhibitors and the design and synthesis of novel P2 ligands for HIV protease inhibitors. Chapter 1 of the dissertation is a concise review of the development and designs incorporated into HIV protease inhibitors. A brief historical background of developing inhibitors for HIV protease is described leading up to FDA second generation protease inhibitors. Also an overview of Ghosh\u27s laboratory contribution to developing potent protease inhibitors and combatting drug resistance is described. Chapter 2 of the dissertation describes the exploratory work performed in designing and synthesizing new novel heterocyclic oxazole P2 ligands for HIV-1 protease inhibitors. Within the ligand is...
Since 1981, HIV/AIDS has affected over 70 million individuals worldwide. Due to the incorporation of...
Based upon molecular insights from the X-ray structures of inhibitor-bound HIV-1 protease complexes,...
Ten years ago, the first protease inhibitor targeting the human immunodeficiency virus (HIV) was app...
The design, synthesis, and biological evaluation of a new class of HIV-1 protease inhibitors contain...
Here, we describe the design, synthesis, and biological evaluation of novel HIV-1 protease inhibitor...
The design, synthesis, and biological evaluation of a new class of HIV-1 protease inhibitors contain...
We have designed, synthesized, and evaluated a new class of potent HIV-1 protease inhibitors with no...
A series of new HIV-1 protease inhibitors (PIs) were designed using a general strategy that combines...
The first part of this thesis describes a novel class of macrocyclic HIV-1 protease inhibitors. A se...
Substituted bis-THF containing protease inhibitors were designed to optimize ligand-enzyme interacti...
In 2018, the World Health Organization (WHO) reported approximately 37 million people are living wit...
Human Immunodeficiency Virus (HIV) is the causative agent of Acquired Immune Deficiency Syndrome (AI...
The proteolytic enzyme of the human immunodeficiency virus (HIV-PR) plays an important role in the H...
A series of novel HIV-1 protease inhibitors based on two pseudosymmetric dipeptide isosteres have be...
The design, synthesis, and biological evaluation of a series of HIV-1 protease inhibitors incorporat...
Since 1981, HIV/AIDS has affected over 70 million individuals worldwide. Due to the incorporation of...
Based upon molecular insights from the X-ray structures of inhibitor-bound HIV-1 protease complexes,...
Ten years ago, the first protease inhibitor targeting the human immunodeficiency virus (HIV) was app...
The design, synthesis, and biological evaluation of a new class of HIV-1 protease inhibitors contain...
Here, we describe the design, synthesis, and biological evaluation of novel HIV-1 protease inhibitor...
The design, synthesis, and biological evaluation of a new class of HIV-1 protease inhibitors contain...
We have designed, synthesized, and evaluated a new class of potent HIV-1 protease inhibitors with no...
A series of new HIV-1 protease inhibitors (PIs) were designed using a general strategy that combines...
The first part of this thesis describes a novel class of macrocyclic HIV-1 protease inhibitors. A se...
Substituted bis-THF containing protease inhibitors were designed to optimize ligand-enzyme interacti...
In 2018, the World Health Organization (WHO) reported approximately 37 million people are living wit...
Human Immunodeficiency Virus (HIV) is the causative agent of Acquired Immune Deficiency Syndrome (AI...
The proteolytic enzyme of the human immunodeficiency virus (HIV-PR) plays an important role in the H...
A series of novel HIV-1 protease inhibitors based on two pseudosymmetric dipeptide isosteres have be...
The design, synthesis, and biological evaluation of a series of HIV-1 protease inhibitors incorporat...
Since 1981, HIV/AIDS has affected over 70 million individuals worldwide. Due to the incorporation of...
Based upon molecular insights from the X-ray structures of inhibitor-bound HIV-1 protease complexes,...
Ten years ago, the first protease inhibitor targeting the human immunodeficiency virus (HIV) was app...